



We believe it is our responsibility to address the health needs of patients and society through transformatonal science: delivering vaccines, medicines that can help millions around the world.

CORE AREAS OF FOCUS

Vaccines

Oncology

Diabetes

Hospital Acute Care

Alzheimer

Over 1,100 employees in Belgium

90% of First in Man clinical studies conducted in Belgium



MSD for Mothers' Commitment

Every two minutes, a woman dies during pregnancy and childbirth. That's more than **800 women a day**. Most of these deaths are preventable when women have access to **quality maternal healthcare**.

To address this crisis, MSD created ***MSD for Mothers***, our **10-year, \$500 million initiative** to create a world where no woman dies giving life.

Over the past six years, ***MSD for Mothers*** has reached more than **six million women in over 30 countries around the world**, contributing to the global effort to save women's lives, strengthen health systems and meet the United Nations' Sustainable Development Goals.



HER LIFE

2.9m women with improved quality of care

3.77m women with access to modern contraception

325k women empowered to demand quality care

HER HEALTHCARE

73.9k providers equipped to offer quality care

HER WORLD

Her infant is fifteen times more likely to survive

Her children are ten times more likely to complete their educations

17m people with access to lifesaving products

21m people with access to quality facilities

Her economy gains millions through increased wages and economic productivity

Her health system saves millions

Her nation is strengthened for future investment

MSD FOR MOTHERS' IMPACT

Bringing the best of MSD to create a world where no woman dies giving life.

6.3 million women reached, and counting

30 Countries

100 Partners

50 Programs

46 Global Health Fellows

500+ Employee Ambassadors

70+ MSD Expert Advisors

35,000+ Employee Hours Contributed



INVENTING FOR LIFE

Project CHAMPION

A new gold standard for treating postpartum hemorrhage


PROJECT SPOTLIGHT

- **Postpartum hemorrhage (PPH)** is the leading cause of maternal mortality. The current standard treatment for the prevention of PPH, Oxytocin, requires cold-chain distribution and storage – a challenge in many low and middle-income countries.
- *Merck for Mothers*, Ferring Pharmaceuticals, and the World Health Organization (WHO) are part of **Project CHAMPION**, a unique public, private-private partnership to invent a **heat-stable formulation of carbetocin** and advance it to market.
- The WHO recently completed a **30,000 women clinical trial** in ten countries to evaluate the effectiveness of heat-stable carbetocin. This is one of – if not the largest – clinical trials ever in this therapeutic area./ **publication pending**
- If the results are successful, we have committed to making heat-stable carbetocin available at an **affordable and sustainable public-sector price**.



A Heat Stable Uterotonic for PPH prevention

Merck for Mothers, Ferring Pharmaceuticals and the HRP/WHO are collaborating to advance a new, heat-stable (HS) formulation of carbetocin



If the trial results are favorable, the Partners will ensure the drug's access:

- WHO will consider the HSC data for inclusion into its Clinical Recommendations for PPH prevention; country equivalents to follow;
- WHO will consider HSC for inclusion into its Essential Medicines List (EML); country equivalents to follow;
- Ferring is responsible for both the Regulatory filing and Manufacturing/Availability. Individual strategies are already in place; execution underway.

How big is the investment?

MSD for Mothers has invested over US \$15M to fund the clinical trial and initial advocacy efforts.

Ferring has invested additional resources in clinical trial support and manufacturing infrastructure.

We estimate that first regulatory approval of the full indication (vaginal and c-section) HSC will be in late 2019.

As a condition of MfM support to fund the trial, Ferring is to provide access to HSC in the public sector of LMICs at an affordable and sustainable price.

